Stable and active metabolites of 1,25-dihydroxy-16-ene-cholecalciferol
AssigneesHoffmann-La Roche Inc., Satyanarayama G. Reddy
InventorsJohn A. McLane, Satyanarayama G. Reddy, Milan R. Uskokovic
Life of this patent
Estimating the term…
Abstract
The invention relates to the compounds 1,25-dihydroxy-16-ene-24-oxo-cholecalciferol and 1,24,25-trihydroxy-16-ene-cholecalciferol which stimulate differentiation of HL-60 cells, rendering them useful as an agent for the treatment of neoplastic diseases such as leukemia, and also decrease proliferation of human keratinocytes, rendering them useful as an agent for the treatment of hyperproliferative disorders of the skin such as psoriasis.
Claims18
1,25-dihydroxy-16-ene-24-oxo-cholecal-ciferol.
A pharmaceutical composition comprising an effective amount of 1,25-dihydroxy-16-ene-24-oxo-cholecalciferol and a carrier material.
A method for stimulating differentiation of HL-60 cells which comprises administering to a host in need of such treatment an effective amount of 1,25-dihydroxy-16-ene-24-oxo-cholecalciferol.
A method for decreasing proliferation of human keratinocytes which comprises administering to a host in need of such treatment an effective amount of 1,25-dihydroxy-16-ene-24-oxo-cholecalciferol.
1,24,25-trihydroxy-16-ene-cholecalciferol.
A pharmaceutical composition comprising an effective amount of 1,24,25-trihydroxy-16-ene-cholecalciferol and a carrier material.
A method for stimulating differentiation of HL-60 cells which comprises administering to a host in need of such treatment an effective amount of 1,24,25-trihydroxy-16-ene-cholecalciferol.
A method for decreasing proliferation of human keratinocytes which comprises administering to a host in need of such treatment an effective amount of 1,24,25-trihydroxy-16-ene-cholecalciferol.
Dependencies are inferred from the claim text.